author-photo

Hiroto Ohguchi

Harvard University

39

Papers

1234

Citations

Citation Trend

Filter By

Papers (23) Sort By

Journal Conference Others

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications.

2021 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (0)
KDM5A reinforces MYC transcriptional program in multiple myeloma

2019
- Hiroto Ohguchi
Show All
- Source
- Cite
- Save
Citations (0)
KDM5A reinforces MYC transcriptional program and promotes myeloma cell growth

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
The biological significance of histone modifiers in multiple myeloma: clinical applications

2018 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (17)
KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival

2017 Leukemia
Show All
- Source
- Cite
- Save
Citations (42)
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications

2017 Leukemia
Show All
- Source
- Cite
- Save
Citations (45)
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (14)
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma

2016 Proceedings of the National Academy of Sciences of the United States of America
Show All
- Source
- Cite
- Save
Citations (79)
The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival

2016 Nature Communications
Show All
- Source
- Cite
- Save
Citations (60)
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.

2015 Leukemia
Show All
- Source
- Cite
- Save
Citations (23)